Comparative Pharmacology
Head-to-head clinical analysis: DYLOJECT versus ZIPSOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYLOJECT versus ZIPSOR.
DYLOJECT vs ZIPSOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis involved in inflammation, pain, and fever. It has no significant inhibition of COX-1 at therapeutic doses.
50 mg intramuscularly every 6 hours as needed for pain; maximum 150 mg per day.
50 mg orally three times daily
None Documented
None Documented
2-4 hours (terminal) in adults; prolonged in elderly (up to 6-8 hours) and hepatic impairment (up to 12 hours).
2-4 hours (terminal); clinical context: short half-life necessitates frequent dosing for sustained relief; prolonged in hepatic impairment
Renal: ~50% as unchanged drug and metabolites (glucuronide conjugates); Biliary/fecal: ~40% as metabolites; <5% unchanged in feces.
Renal: ~60% unchanged; biliary/fecal: ~30% as metabolites; remainder as glucuronide conjugates
Category C
Category C
NSAID
NSAID